Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection

Journal of Biomedical Science - Tập 28 Số 1 - 2021
Neda Gholizadeh1, Peter Greer2, John B. Simpson2, Jonathan Goodwin2, Caixia Fu3, Peter Lau4, Saabir Siddique4, Arend Heerschap5, Saadallah Ramadan6
1School of Health Sciences, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia
2School of Mathematical and Physical Sciences, University of Newcastle, Newcastle, NSW, Australia
3MR Application Development, Siemens Shenzhen Magnetic Resonance Ltd., Shenzhen, China
4Radiology Department, Calvary Mater Newcastle, Newcastle, NSW, Australia
5Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
6Hunter Medical Research Institute (HMRI) Imaging Centre, New Lambton Heights, NSW, Australia

Tóm tắt

Abstract Background Current multiparametric MRI (mp-MRI) in routine clinical practice has poor-to-moderate diagnostic performance for transition zone prostate cancer. The aim of this study was to evaluate the potential diagnostic performance of novel 1H magnetic resonance spectroscopic imaging (MRSI) using a semi-localized adiabatic selective refocusing (sLASER) sequence with gradient offset independent adiabaticity (GOIA) pulses in addition to the routine mp-MRI, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and quantitative dynamic contrast enhancement (DCE) for transition zone prostate cancer detection, localization and grading. Methods Forty-one transition zone prostate cancer patients underwent mp-MRI with an external phased-array coil. Normal and cancer regions were delineated by two radiologists and divided into low-risk, intermediate-risk, and high-risk categories based on TRUS guided biopsy results. Support vector machine models were built using different clinically applicable combinations of T2WI, DWI, DCE, and MRSI. The diagnostic performance of each model in cancer detection was evaluated using the area under curve (AUC) of the receiver operating characteristic diagram. Then accuracy, sensitivity and specificity of each model were calculated. Furthermore, the correlation of mp-MRI parameters with low-risk, intermediate-risk and high-risk cancers were calculated using the Spearman correlation coefficient. Results The addition of MRSI to T2WI + DWI and T2WI + DWI + DCE improved the accuracy, sensitivity and specificity for cancer detection. The best performance was achieved with T2WI + DWI + MRSI where the addition of MRSI improved the AUC, accuracy, sensitivity and specificity from 0.86 to 0.99, 0.83 to 0.96, 0.80 to 0.95, and 0.85 to 0.97 respectively. The (choline + spermine + creatine)/citrate ratio of MRSI showed the highest correlation with cancer risk groups (r = 0.64, p < 0.01). Conclusion The inclusion of GOIA-sLASER MRSI into conventional mp-MRI significantly improves the diagnostic accuracy of the detection and aggressiveness assessment of transition zone prostate cancer.

Từ khóa


Tài liệu tham khảo

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;2:897–906.

Augustin H, Erbersdobler A, Hammerer PG, Graefen M, Huland H. Prostate cancers in the transition zone: Part 2; clinical aspects. BJU Int. 2004;94:1226–9.

Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010;257:715–23.

Gordetsky JB, Thomas JV, Nix JW, Rais-Bahrami S. Higher prostate cancer grade groups are detected in patients undergoing multiparametric MRI-targeted biopsy compared with standard biopsy. Am J Surg Pathol. 2017;41:101–5.

Panebianco V, Giganti F, Kitzing YX, Cornud F, Campa R, De Rubeis G, et al. An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. Insights Imaging. 2018;9:87–101.

Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, et al. Intra- and interreader reproducibility of PI-RADSv2: a multireader study. J Magn Reson Imaging. 2019;49:1694–703.

Bourne R, Panagiotaki E. Limitations and Prospects for Diffusion-Weighted MRI of the Prostate. Diags. 2016;6:21.

Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roentgenol. 2012;198:1277–88.

Kobus T, Wright AJ, Scheenen TW, Heerschap A. Mapping of prostate cancer by 1H MRSI. NMR Biomed. 2014;27:39–52.

Kurhanewicz J, Vigneron DB. Magnetic resonance spectroscopy of prostate cancer. eMagRes. 2016;1:923–44.

Steinseifer IK, van Asten JJ, Weiland E, Scheenen TW, Maas MC, Heerschap A. Improved volume selective 1H MR spectroscopic imaging of the prostate with gradient offset independent adiabaticity pulses at 3 tesla. Magn Reson Med. 2015;74:915–24.

Gholizadeh N, Fuangrod T, Greer PB, Lau P, Ramadan S, Simpson J. An inter-centre statistical scale standardisation for quantitatively evaluating prostate tissue on T2-weighted MRI. Australas Phys Eng Sci Med. 2019;42:137–47.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.

Gholizadeh N, Greer PB, Simpson J, Fu C, Al-iedani O, Lau P, et al. Supervised risk predictor of central gland lesions in prostate cancer using (1) H MR spectroscopic imaging with gradient offset-independent adiabaticity pulses. J Magn Reson Imaging. 2019;50:1926–36.

Ueno Y, Tamada T, Bist V, Reinhold C, Miyake H, Tanaka U, et al. Multiparametric magnetic resonance imaging: current role in prostate cancer management. Int J Urol. 2016;23:550–7.

Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, et al. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard. NMR Biomed. 2017;30:e3796.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. Eur Urol. 2019;75:385–96.

Hoeks CM, Vos EK, Bomers JG, Barentsz JO, de Kaa CA, Scheenen TW. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens. Invest Radiol. 2013;48:693–701.

Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–58.

Rosenkrantz AB, Kim S, Campbell N, Gaing B, Deng FM, Taneja SS. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. Am J Roentgenol. 2015;204:W266–72.

Gholizadeh N, Pundavela J, Nagarajan R, Dona A, Quadrelli S, Biswas T, et al. Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: potential role in the diagnosis and management of prostate cancer. Urol Oncol. 2020;38:150–73.

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate imaging-reporting and data system version 2 and the implementation of high-quality prostate magnetic resonance imaging. Eur Urol. 2017;72:189–91.

Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, et al. Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging. 2013;37:1035–54.

Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol. 2011;196:374–81.

Tamada T, Sone T, Jo Y, Yamamoto A, Ito K. Diffusion-weighted MRI and its role in prostate cancer. NMR Biomed. 2014;27:25–38.

Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiol. 2006;239:784–92.

Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411–8.

Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol. 2008;49:1207–13.

Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Head-to-head comparison between high- and standard-b-value dwi for detecting prostate cancer: a systematic review and meta-analysis. Am J Roentgenol. 2017;210:91–100.

Hoeks CM, Hambrock T, Yakar D, van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013;266:207–17.

Maas MC, Litjens GJ, Wright AJ, Attenberger UI, Haider MA, Helbich TH, et al. A single-arm, multicenter validation study of prostate cancer localization and aggressiveness with a quantitative multiparametric magnetic resonance imaging approach. Invest Radiol. 2019;54:437–47.

Kobus T, Vos PC, Hambrock T, De Rooij M, Van de Kaa CA, Barentsz JO, et al. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiol. 2012;265:457–67.

Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818–24.

Scheenen TW, Fütterer J, Weiland E, Van Hecke P, Lemort M, Zechmann C, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol. 2011;46:25–33.

Riches SF, Payne GS, Morgan VA, Sandhu S, Fisher C, Germuska M, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. Am J Roentgenol. 2009;193:1583–91.

Vos EK, Kobus T, Litjens GJ, Hambrock T, van de Kaa CA, Barentsz JO, et al. Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol. 2015;50:490–7.

Lagemaat MW, Zechmann CM, Fütterer JJ, Weiland E, Lu J, Villeirs GM, et al. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5 T. J Magn Reson Imaging. 2012;35:166–73.

Tayari N, Steinseifer IK, Selnæs KM, Bathen TF, Maas MC, Heerschap A. High-quality 3-dimensional 1H magnetic resonance spectroscopic imaging of the prostate without endorectal receive coil using a semi-LASER sequence. Invest Radiol. 2017;52:640–6.

Thông tin
Thông tin xuất bản

Journal of Biomedical Science

Tập 28 Số 1

Thông tin tác giả